Journal Article Review Epublish 27 citations
PubMed: 36900189 DOI: 10.3390/cancers15051397
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology.
Cancers (Basel) 15(5)
Authors: Vincenzo Quagliariello, Irma Bisceglia, Massimiliano Berretta, Martina Iovine, Maria Laura Canale, Carlo Maurea, Vienna Giordano, Andrea Paccone, Alessandro Inno, Nicola Maurea
Affiliations
- Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy.
- Servizi Cardiologici Integrati, Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliera San Camillo Forlanini, 00152 Roma, Italy.
- Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy.
- U.O.C. Cardiology Department, Ospedale Versilia, Lido di Camaiore (LU), 55049 Camaiore, Italy.
- Department of Neurology, University of Salerno, 84084 Fisciano, Italy.
- Medical Oncology Department, IRCCS Ospedale Sacro Cuore Don Calabria, 37024 Negrar di Valpolicella, Italy.
Abstract
Cancer patients treated with immune checkpoint inhibitors (ICIs) are exposed to a high risk of atherosclerosis and cardiometabolic diseases due to systemic inflammatory conditions and immune-related atheroma destabilization. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key protein involved in metabolism of low-density lipoprotein (LDL) cholesterol. PCSK9 blocking agents are clinically available and involve monoclonal antibodies, and SiRNA reduces LDL levels in high-risk patients and atherosclerotic cardiovascular disease events in multiple patient cohorts. Moreover, PCSK9 induces peripheral immune tolerance (inhibition of cancer cell- immune recognition), reduces cardiac mitochondrial metabolism, and enhances cancer cell survival. The present review summarizes the potential benefits of PCSK9 inhibition through selective blocking antibodies and siRNA in patients with cancer, especially in those treated with ICIs therapies, in order to reduce atherosclerotic cardiovascular events and potentially improve ICIs-related anticancer functions.
MeSH
Antibodies, Risk, Cholesterol, Ldl, Lipoproteins, Ldl, Cells, Neoplasms, Atherosclerosis, Immune Checkpoint Inhibitors
Cited by
- Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall. Int J Mol Sci, 2024
- PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition. Int J Mol Sci, 2025
- The impact of immune checkpoint inhibition on atherosclerosis in cancer patients. Front Immunol, 2025
- Cholesterol metabolism-related genes predict immune infiltration and prognosis in gastric cancer patients. J Cancer, 2025
- Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection. Microb Cell Fact, 2024
- Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma. J Transl Med, 2025
- Five-Year Efficacy and Safety of TiNO-Coated Stents Versus Drug-Eluting Stents in Acute Coronary Syndrome: A Meta-Analysis. J Clin Med, 2023
- Association Between Shift Work and Acute Coronary Syndrome According to Alcohol Intake and Smoking. Medicina (Kaunas), 2025
- Risk Factors and Prevention of Cancer and CVDs: A Chicken and Egg Situation. J Clin Med, 2025
- Optimal calorie restriction threshold: effect of FATmax exercise combined with different proportions of calorie restriction on hypercholesterolemia. Front Physiol, 2025
- PCSK9 Manipulates Lipid Metabolism and the Immune Microenvironment in Cancer. Onco Targets Ther, 2025
- In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy. Cancers (Basel), 2025
- Cardiotoxicity Associated with Immune Checkpoint Inhibitors. Cancers (Basel), 2023
- Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors. Nat Cardiovasc Res, 2024
- Assessment of Native Myocardial T1 Mapping for Early Detection of Anthracycline-Induced Cardiotoxicity in Patients with Cancer: a Systematic Review and Meta-analysis. Cardiovasc Toxicol, 2024
- The Association between Major Adverse Cardiovascular Events and Peripheral Artery Disease Burden. J Cardiovasc Dev Dis, 2024
- MicroRNAs in Myocarditis-Review of the Preclinical In Vivo Trials. Biomedicines, 2023